Qui­et Cin­Cor Phar­ma makes some noise with $143M, new tri­al plans for blood pres­sure drug

Cin­Cor Phar­ma has been fair­ly qui­et since emerg­ing in the hy­per­ten­sion space a cou­ple of years ago with a for­mer Roche pro­gram in tow. Not any­more.

On Tues­day, the Cincin­nati-based biotech un­wrapped a $143 mil­lion Se­ries B round led by Gen­er­al At­lantic. And judg­ing by the size of the raise and the syn­di­cate of blue-chip in­vestors, it seems like­ly that CEO Marc de Garidel has the S-1 pa­pers ready to go.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER